RÉSUMÉ
Although rare, CALM/AF10 is a chromosomal rearrangement found in immature T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia, and mixed phenotype acute leukemia of T/myeloid lineages with poor prognosis. Moreover, this translocation is detected in 50% of T-ALL patients with gamma/delta T cell receptor rearrangement, frequently associated with low expression of transcription factor CCAAT/enhancer-binding protein alpha (CEBPA). However, the relevance of CEBPA low expression for CALM/AF10 leukemogenesis has not yet been evaluated. We generated double mutant mice, which express the Lck-CALM/AF10 fusion gene and are haploinsufficient for the Cebpa gene. To characterize the hematopoiesis, we quantified hematopoietic stem cells, myeloid progenitor cells, megakaryocyte-erythrocyte progenitor cells, common myeloid progenitor cells, and granulocyte-macrophage progenitor cells. No significant difference was detected in any of the progenitor subsets. Finally, we tested if Cebpa haploinsufficiency would lead to the expansion of Mac-1+/B220+/c-Kit+ cells proposed as the CALM/AF10 leukemic progenitor. Less than 1% of bone marrow cells expressed Mac-1, B220, and c-Kit with no significant difference between groups. Our results showed that the reduction of Cebpa gene expression in Lck-CALM/AF10 mice did not affect their hematopoiesis or induce leukemia. Our data corroborated previous studies suggesting that the CALM/AF10 leukemia-initiating cells are early progenitors with lymphoid/myeloid differentiating potential.
Sujet(s)
Animaux , Lapins , Leucémie aigüe myéloïde/génétique , Protéine alpha liant les séquences stimulatrices de type CCAAT/génétique , Haploinsuffisance/génétique , Hématopoïèse/génétique , Phénotype , Facteurs de transcription/génétique , Translocation génétique/génétique , Souris transgéniques , Maladie aigüe , Cytométrie en flux , GénotypeRÉSUMÉ
Micro-ribonucleic acids (microRNAs) are small molecules containing 20-23 nucleotides. Despite their small size, it is likely that almost every cellular process is regulated by them. Moreover, aberrant microRNA expression has been involved in the development of various diseases, including cancer. Although many data are available about the role of microRNAs in various lymphoproliferative disorders, their impact on the development of acute lymphoblastic leukemia of T-cell progenitors is largely unknown. In this review, we present recent information about how specific microRNAs are expressed and regulated during malignant T-lymphopoiesis and about their role during normal hematopoiesis.
Sujet(s)
Humains , Régulation de l'expression des gènes dans la leucémie/génétique , Hématopoïèse/génétique , microARN/physiologie , Leucémie-lymphome lymphoblastique à précurseurs T/génétique , ARN tumoral/génétique , Marqueurs biologiques tumoraux/génétique , microARN/génétique , Leucémie-lymphome lymphoblastique à précurseurs T/anatomopathologieRÉSUMÉ
Acute promyelocytic leukemia (APL) is characterized by the expansion of blasts that resemble morphologically promyelocytes and harbor a chromosomal translocation involving the retinoic acid receptor a (RARa) and the promyelocytic leukemia (PML) genes on chromosomes 17 and 15, respectively. The expression of the PML/RARa fusion gene is essential for APL genesis. In fact, transgenic mice (TM) expressing PML/RARa develop a form of leukemia that mimics the hematological findings of human APL. Leukemia is diagnosed after a long latency (approximately 12 months) during which no hematological abnormality is detected in peripheral blood (pre-leukemic phase). In humans, immunophenotypic analysis of APL blasts revealed distinct features; however, the precise immunophenotype of leukemic cells in the TM model has not been established. Our aim was to characterize the expression of myeloid antigens by leukemic cells from hCG-PML/RARa TM. In this study, TM (N = 12) developed leukemia at the mean age of 13.1 months. Morphological analysis of bone marrow revealed an increase of the percentage of immature myeloid cells in leukemic TM compared to pre-leukemic TM and wild-type controls (48.63 ± 16.68, 10.83 ± 8.11, 7.4 ± 5.46 percent, respectively; P < 0.05). Flow cytometry analysis of bone marrow and spleen from leukemic TM identified the asynchronous co-expression of CD34, CD117, and CD11b. This abnormal phenotype was rarely detected prior to the diagnosis of leukemia and was present at similar frequencies in hematologically normal TM and wild-type controls of different ages. The present results demonstrate that, similarly to human APL, leukemic cells from hCG-PML/RARa TM present a specific immunophenotype.
Sujet(s)
Animaux , Souris , Antigènes CD/immunologie , Leucémie aigüe myéloïde/immunologie , Leucémie aiguë promyélocytaire/immunologie , Protéines de fusion oncogènes/immunologie , Antigènes CD/génétique , Moelle osseuse/immunologie , Moelle osseuse/anatomopathologie , Cathepsines , Cytométrie en flux , Génotype , Immunophénotypage , Leucémie aigüe myéloïde/génétique , Leucémie aiguë promyélocytaire/génétique , Souris transgéniques , Protéines de fusion oncogènes/génétique , Serine endopeptidases , Rate/immunologie , Rate/anatomopathologieRÉSUMÉ
The distinction between normal and leukemic bone marrow (BM) B-precursors is essential for the diagnosis and treatment monitoring of acute lymphoblastic leukemia (ALL). In order to evaluate the potential use of quantitative fluorescence cytometry (QFC) for this distinction, we studied 21 normal individuals and 40 patients with CD10+ ALL. We characterized the age-related changes of the CD10, CD19, TdT, CD34 and CD79a densities in normal and leukemic BM. Compared to normal adults, the B-precursors from normal children expressed significantly lower values of CD34-specific antibody binding capacity (SABC) (median value of 86.6 vs 160.2 arbitrary units (a.u.) in children and adults, respectively). No significant age-related difference was observed in the expression of the other markers in the normal BM, or in any of the markers in the leukemic BM. Based on the literature, we set the cut-off value for the normal CD10 expression at 45 x 10Ý a.u. for both age groups. For the remaining markers we established the cut-off values based on the minimum-maximum values in the normal BM in each age group. The expression of CD10 was higher than the cut-off in 30 ALL cases and in 18 of them there was a concomitant aberrant expression of other markers. In 9 of the 10 CD10+ ALL with normal CD10 SABC values, the expression of at least one other marker was aberrant. In conclusion, the distinction between normal and leukemic cells by QFC was possible in 38/40 CD10+ ALL cases
Sujet(s)
Humains , Nourrisson , Enfant d'âge préscolaire , Enfant , Adolescent , Adulte , Adulte d'âge moyen , Antigènes CD/analyse , Cellules de la moelle osseuse , Cytométrie en flux , Immunophénotypage , Leucémie-lymphome lymphoblastique à précurseurs B et T , Marqueurs biologiques , Études cas-témoins , Technique d'immunofluorescence , Technique d'immunofluorescence directe , Immunoélectrophorèse bidimensionnelle , Modèles linéaires , Maladie résiduelle/diagnostic , Statistique non paramétrique , Sternum/cytologieRÉSUMÉ
1. The effects of cinnarizine and nifedipine on the nociceptive threshold and opiate antinociception were e evaluated by the rat rail-flick test. 2. male Wistar rats (390-410 g) treated with intraperitoneal (ip) or intrathecal (it) cinnarizine, but not with it nifedipine, displayed a dose-dependent antinociception. The estimated AD50 values of cinnarizine were 3.55 microng/Kg (coeficience limits, 1.99 to 6.32) and 125.9 microng/Kg (46.1 to 343.7) for the it and ip routs of administration, respectively. The effect of it cinnarizine was reduced by subsequent it administration of calcium chloride (0.1 micron mol). 3. The it morphine-induced antinociception was potentiated by the previous it adminsitration of cinnarizine (1.0 micring/rat). The stimated AD50 if morphine was reduced from 10.4 (6.8 to 16.1) to 4.9 microng (3.6 to 6.5) by this dose of cinnarizine. The calculated potency ratio for these values was 2.14 (1.28 to 3.57). A similar potentiation was obtained with it nifedipine, but only when drug was injected in combination with morphine. 4. It is concluded that the antinociception evoked by a systemically injected calcium channel blocker is dependent on passage of the drug across the blood brain barrier to act, at least in part, at a spinal site of action. 5. The mechanism of the antinociception induced by it injected calcium channel blockers appears to depend on the interaction of the drugs with Ca2+ binding sites in the spinal cord and, probably, on the type of voltage-sensitive calcium channel involved